CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s ...
Raymond James downgraded Editas Medicine ( EDIT, Financials) from outperform to market perform, citing extended development ...
CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...
Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...
Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...
Khaleej Times on MSN3d
UAE to introduce genetic testing in pre-marital screening for all citizens starting January 2025Starting January 2025, genetic testing will be an essential part of the premarital screening programme for all UAE citizens ...
Newborn screening is a fundamental right for every child, crucial for early diagnosis and intervention of preventable ...
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ...
Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback